证券代码：300298 证券简称：三诺生物 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司投资者关系活动记录表 编号：2022-06-01 | --- | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资 ...

编号：2022-07-02 证券代码：300298 证券简称：三诺生物 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------------------------------------------|-----------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 \n□ 现场参观 | □ 分析师会议 \n□ 业绩说明会 \n□ 路演活动 \n□ 其他（请文字说明其他活动内容） | | | 睿远基金：钟明、袁媛 | | | | 中金资管：杨钟男 | | | | 建信基金：郑丁源 | | | | 希瓦资产：田闯 | | | | 混沌资产：张肖星 | | | | 中信自营：宋彦博 | | | | 望正资产：高敏 | | | | 兴业证券：孙媛媛、嵇肖潇 | | | ...

编号：2022-07-01 证券代码：300298 证券简称：三诺生物 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 \n□ 现场 ...

编号：2022-08-03 证券代码：300298 证券简称：三诺生物 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | 现场参观 | □ 其他（请文字说明其他活动内容） | | | | 深圳证券交易所：张雪峰、黄祖鹏、王腾 | | 参与单位名称及 人员姓名 | ...

证券代码：300298 证券简称：三诺生物 债券代码：123090 债券简称：三诺转债 编号：2022-08-02 三诺生物传感股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------------|----------------------------------| | | 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 其他（请文字说明其他活动内容） | | | 华泰证券：代雯、高鹏、杨昌源 | | | | 富国证券：李淼 | | | | 嘉实基金：牛歌、郝淼 | | | | 华夏基金：常黎曼 | | | | 华商基金：孙蔚 | | | | 平安资产：俞冰 银华基金：薄官辉 | | | | 泰康资产：陈璟 | | | | 博时基金：陈西铭 | | | | 淡水泉投资：王沛 | | | | 金鹰基金：杨凡 | | | 参与单位名称及 | 重阳投资：方溢涵 | | | | ...

Financial Performance - Revenue for Q3 2022 reached ¥688,579,127.87, an increase of 11.38% year-over-year, while total revenue for the year-to-date was ¥1,980,530,135.94, up 13.23% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2022 was ¥153,470,946.83, representing a significant increase of 97.16% year-over-year, with a year-to-date net profit of ¥363,402,542.22, up 84.60%[4]. - The basic earnings per share for Q3 2022 was ¥0.2754, an increase of 99.57% compared to the same period last year, while the diluted earnings per share also stood at ¥0.2754[4]. - Operating profit for Q3 2022 was ¥395,736,205.01, up 94.39% year-over-year, driven by increased revenue and investment income[9]. - Net profit for the period was CNY 363,176,064.00, compared to CNY 196,550,398.85 in the same period last year, representing an increase of 84.8%[35]. - Earnings per share (EPS) for the period was CNY 0.6499, up from CNY 0.3489 in the previous year, indicating a significant improvement in profitability[35]. Assets and Equity - The company's total assets as of September 30, 2022, were ¥4,488,728,026.27, reflecting an 8.07% increase from the end of the previous year[4]. - The company's total equity attributable to shareholders increased to ¥3,070,318,315.88, a rise of 10.22% from the end of the previous year[4]. - The company's total assets reached RMB 4,488.73 million as of September 30, 2022, compared to RMB 4,153.51 million at the beginning of the year[31]. - The total equity attributable to shareholders of the parent company rose to CNY 3,070,318,315.88, compared to CNY 2,785,671,986.48, marking an increase of 10.3%[32]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥352,578,588.84, an increase of 84.96% compared to the same period last year[4]. - The cash inflow from operating activities totaled CNY 2,156,263,232.40, an increase from CNY 1,778,397,923.26 in the previous year, representing a growth of approximately 21.3%[37]. - The net cash flow from operating activities was CNY 352,578,588.84, compared to CNY 190,619,407.31 in the same period last year, indicating a significant increase of about 84.9%[37]. - The cash inflow from investment activities totaled ¥321,410,374.30, reflecting a 108.67% increase, mainly driven by the redemption of financial products by the parent company[11]. - The cash outflow from investing activities was CNY 393,331,125.46, down from CNY 572,244,702.06, showing a reduction of approximately 31.3%[38]. - The total cash and cash equivalents at the end of the period amounted to CNY 514,124,568.01, down from CNY 634,868,492.55 in the previous year, a decrease of about 19.0%[38]. Investment Income - Investment income for Q3 2022 was ¥59,377,166.73, a substantial increase of 286.34% compared to the previous year, primarily due to compensation received from a subsidiary[9]. - The company reported investment income of CNY 59,377,166.73, a recovery from a loss of CNY 31,864,684.38 in the same period last year[34]. - The cash inflow from investment income increased by 215.31% to ¥3,216,192.28, attributed to higher returns from redeemed financial products[11]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,905[12]. - The largest shareholder, Li Shaobo, holds 25.29% of the shares, amounting to 142,685,648 shares, with 92,585,000 shares pledged[13]. - The company repurchased a total of 6,999,287 shares, accounting for 1.24% of the total share capital of 564,221,835 shares, with a total transaction amount of RMB 168,585,184.23[20]. Research and Development - Research and development expenses for the period were CNY 183,462,004.12, up from CNY 143,218,412.66, reflecting a year-over-year increase of 28.1%[34]. Financial Management - The company reported a significant reduction in financial expenses, down 102.39% to -¥771,948.28, mainly due to decreased interest expenses[9]. - The cash received from tax refunds was CNY 39,248,524.61, compared to CNY 21,132,926.18 in the previous year, representing an increase of approximately 85.7%[37].

证券代码：300298 证券简称：三诺生物 公告编号：2022-080 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司 关于参加湖南辖区上市公司2022年 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与广大投资者的互动交流，使广大投资者能更深入全面地了解公 司情况，三诺生物传感股份有限公司（以下简称"公司"）将参加由中国证券监督 管理委员会湖南监管局、湖南省上市公司协会与深圳市全景网络有限公司联合举办 的"湖南辖区上市公司2022年投资者网上集体接待日活动"，现将有关事项公告如 下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互联网 平 台 ， 采 取 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 以 登 录 " 全 景 路 演 " 网 站 （http://rs.p5w.net）参与公司本次投资者网上接待日活动，活动时间为2022年9月29 日（星期四）15:30-17:00。 届时公司董事会秘书兼财务总监黄安国先生、证券事务代表许卉雨女士及相关 工作人员将通过网络 ...

Financial Performance - The company reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15% compared to RMB 1.04 billion in the same period of 2021[2]. - The net profit attributable to shareholders for the first half of 2022 was RMB 300 million, up 20% from RMB 250 million in the first half of 2021[2]. - The company's operating revenue for the first half of 2022 was CNY 1,291,951,008.07, representing a 14.25% increase compared to CNY 1,130,848,419.54 in the same period last year[13]. - The net profit attributable to shareholders was CNY 209,931,595.39, a significant increase of 76.39% from CNY 119,013,680.49 in the previous year[13]. - The net cash flow from operating activities was CNY 62,283,368.08, reflecting a 28.81% increase compared to CNY 48,352,334.15 in the same period last year[13]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-on-year growth of 25%[64]. - Future outlook indicates a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[63]. User Growth and Market Expansion - The company achieved a total of 5 million users for its blood glucose monitoring systems, marking a 25% increase from 4 million users in the previous year[2]. - User data indicates that the number of active users for the company's products has reached 5 million, an increase of 15% compared to the previous year[64]. - The company is expanding its market presence in Southeast Asia, with a target to increase sales by 30% in this region by the end of 2023[2]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[62]. - The company is actively expanding its overseas market presence, particularly in Southeast Asia, North America, and Mexico, through strategic partnerships and cross-border e-commerce[40]. Research and Development - The R&D expenditure for the first half of 2022 was RMB 150 million, accounting for 12.5% of total revenue, reflecting the company's commitment to innovation[2]. - In the first half of 2022, the company's R&D investment reached 119.49 million yuan, accounting for 9.25% of total revenue, with 808 R&D personnel representing 22.52% of total staff[47]. - Research and development investments increased by 30% in 2022, focusing on innovative diagnostic technologies[63]. - The company has applied for 18 patents in China in the first half of 2022, including 11 invention patents, and has been granted 26 new patents[50]. Product Development and Innovation - The company plans to launch a new continuous glucose monitoring system by the end of 2022, aiming to capture a larger market share in the diabetes management sector[2]. - The company has transitioned from a blood glucose monitoring system provider to a provider of multi-indicator detection systems for chronic diseases[31]. - The company’s iPOCT system can currently detect over 70 indicators, expanding its product offerings beyond just blood glucose monitoring[32]. - The company has developed a diverse product line, including home blood glucose monitoring products and various chronic disease testing systems[33]. - The company has launched a series of new medical devices, including a portable multifunctional testing instrument and a blood glucose meter, with regulatory approvals valid until 2024 and beyond[21][22]. - The company is focusing on diabetes management solutions, including a diabetes management system software that supports data recording and analysis, expected to launch in September 2026[32]. Strategic Partnerships and Collaborations - The company has initiated a strategic partnership with a leading healthcare provider to enhance its distribution network and improve customer access to its products[2]. - The company collaborates with over 80 pharmaceutical companies to expand its chronic disease detection product offerings and improve patient care[42]. - The company has established a diabetes management system in over 600 hospitals, improving blood glucose testing efficiency through digital solutions[43]. Quality Control and Compliance - The company has implemented a centralized procurement management system to ensure product quality and reduce costs through global sourcing[37]. - The production process adheres to ISO:13485:2016 standards and incorporates smart manufacturing technologies to enhance product quality and innovation[38]. - The company emphasizes the importance of regulatory compliance, with all products receiving necessary approvals from health authorities[21][22][23]. Financial Management and Investments - The company does not plan to distribute cash dividends for the fiscal year 2022, focusing instead on reinvestment for growth[2]. - The company has invested CNY 119.49 million in R&D in the first half of 2022, representing a year-on-year increase of 31.86%, accounting for 9.25% of total revenue[81]. - The company has completed a strategic acquisition of a smaller biotech firm, which is expected to contribute an additional 200 million RMB in revenue annually[64]. Market Trends and Industry Insights - The global adult diabetes population reached 537 million in 2021, with projections indicating an increase to 643 million by 2030, highlighting a growing market for the company's products[22]. - The number of diabetes patients in China increased from 90 million in 2011 to 140 million in 2021, a growth of 56%[23]. - The penetration rate of blood glucose meters among diabetes patients in China is only about 25%, compared to 90% in Europe and the US[26]. - The Chinese blood glucose monitoring market is expected to reach 10 billion yuan by 2025[26]. Operational Efficiency - The gross margin for the first half of 2022 was reported at 60%, compared to 58% in the same period last year, indicating improved cost efficiency[2]. - The company aims to achieve a net profit margin of 15% by the end of 2023, supported by operational efficiencies and increased sales volume[63]. - The company has implemented a comprehensive quality management system upgrade to meet international standards and improve process control[53]. Risk Management - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[2]. - The company faces intensified competition in the POCT monitoring product industry, which may impact its operating performance if it fails to enhance its technological and management capabilities[119]. - The company faces risks related to strict regulatory requirements in the medical device industry, which could impact its operations if not properly managed[126].

Financial Performance - In 2021, the company achieved operating revenue of 2.361 billion RMB, a year-on-year increase of 17.17%[2] - The net profit attributable to shareholders was 107 million RMB, a significant decline of 42.44% compared to the previous year, marking the largest drop since the company went public[2] - The company's operating revenue for 2021 was ¥2,361,308,058.17, representing a 17.17% increase compared to ¥2,015,214,106.51 in 2020[17] - The net profit attributable to shareholders for 2021 was ¥107,569,179.71, a decrease of 42.44% from ¥186,890,338.05 in 2020[17] - The net profit after deducting non-recurring gains and losses was ¥96,086,548.23, down 45.10% from ¥175,008,490.09 in the previous year[17] - The company's total assets at the end of 2021 were ¥4,153,513,571.28, an increase of 6.61% from ¥3,895,941,072.32 at the end of 2020[17] - The basic earnings per share for 2021 was ¥0.1916, a decline of 42.65% compared to ¥0.3341 in 2020[17] - The company reported a net cash flow from operating activities of ¥480,028,164.20, which is a decrease of 4.88% from ¥504,641,320.17 in 2020[17] - The company's operating profit and total profit for the reporting period were CNY 139.28 million and CNY 138.18 million, representing a year-on-year decline of 41.04% and 44.23% respectively[62] Strategic Focus and Growth Initiatives - The company is focusing on maintaining growth in its primary business while ensuring the healthy development of its second growth curve through digital transformation[2] - The digital transformation strategy aims to enhance operational efficiency and quality by connecting instruments, data, and services, leveraging big data, cloud computing, and AI[3] - The company plans to redefine its strategic core organizational capabilities as professional, digital, and global to adapt to market demands[4] - The second growth curve is based on a precision wearable system (PWS) for diabetes management, with a global layout to enhance its position as a digital management expert[5] - Sinocare plans to expand its market presence in Latin America, targeting a 15% market share by 2025[11] - The company is investing RMB 200 million in R&D for new diabetes management technologies, aiming to launch two new products in 2022[12] - The company is exploring potential acquisitions in the health tech sector to diversify its product portfolio and enhance its competitive edge[11] Product Development and Innovation - The company has developed an integrated full-course management solution that combines inpatient blood glucose management with outpatient self-monitoring, facilitating patient self-management of chronic diseases[41] - The company has launched over 20 sub-brands across 5 product lines, covering more than 70 testing indicators including blood glucose, blood lipids, and uric acid[56] - The company is focusing on multi-platform product development, including electrochemical and fluorescence platforms, to expand its iPOCT product line[71] - The company has introduced a unique "5+1+2" diabetes management service model, leveraging a self-developed diabetes assessment system[55] - The company is actively expanding its POCT testing business to meet the needs of grassroots medical units and home healthcare, reinforcing its business development[38] - The company is committed to continuous innovation in its product offerings, with several new testing kits set to be launched in the near future[98] Market Expansion and Competitive Position - The company has expanded its global business presence to 135 countries and regions, following acquisitions of Trividia Health Inc. and PTS in the U.S.[52] - The company is actively promoting brand awareness through various marketing initiatives, including partnerships with e-commerce platforms and health campaigns[69] - The company is expanding its market presence in the retail sector in China and the third-party testing market in the U.S., while also targeting hospital and grassroots medical markets[61] - The company aims to improve chronic disease management through a digital health management platform, integrating IoT and AI technologies[66] - The company is focused on establishing a global marketing system in collaboration with Sinocare, PTS, and Trividia, particularly targeting the Asia-Pacific region[152] Research and Development - As of December 31, 2021, the company had 758 R&D personnel, accounting for 21.45% of total employees, with R&D investment of ¥182.43 million, representing 7.73% of total revenue[48] - The company applied for 58 patents in China in 2021, including 15 invention patents, and received 59 patent authorizations[72] - The company is focused on maintaining high-quality standards for its products, as evidenced by the quality control measures implemented for its testing systems[96] - The company has a strong focus on research and development in the healthcare sector, as indicated by the qualifications of its board members[192] Financial Management and Governance - The company has established a performance evaluation and incentive mechanism for its board members and senior management, ensuring transparency and compliance with legal regulations[173] - The company emphasizes the protection of stakeholder rights and has established diverse communication channels with employees to balance interests among shareholders, employees, and society[174] - The audit committee under the board is responsible for overseeing internal and external audits, ensuring the authenticity and completeness of financial information[175] - The company has a dedicated investor relations management system, enhancing transparency and communication with investors through various channels[176] Regulatory Compliance and Quality Assurance - The company has established a quality management system that aligns with international standards, enhancing process control and product quality assurance[73] - The company is committed to maintaining high standards in product quality and regulatory compliance during the registration process[101] - The company has received approval for multiple medical testing kits, including the Glycated Hemoglobin Test Kit and the Lipid Panel Test Kit, with registration changes approved on December 22, 2021[94] Future Outlook - The company provided a positive outlook for 2022, projecting a revenue growth of 20% driven by new product launches and market expansion[92] - The company aims to achieve a revenue target of RMB 2.7 billion in 2022, focusing on steady growth in overall sales and operating profit[150] - The company plans to explore strategic acquisitions to enhance its product portfolio and technological capabilities in the next fiscal year[88]

Revenue and Profit - Revenue for Q1 2022 reached ¥619,755,536.06, an increase of 23.27% compared to ¥502,767,712.79 in the same period last year[2] - Net profit attributable to shareholders was ¥65,293,271.66, up 45.22% from ¥44,960,957.80 year-on-year[2] - Net profit after deducting non-recurring gains and losses was ¥60,043,604.57, representing a 57.01% increase from ¥38,242,503.39 in the previous year[2] - Basic earnings per share increased by 47.16% to ¥0.1164 from ¥0.0791 in the same period last year[2] - The net profit for Q1 2022 was CNY 65,209,096.74, an increase of 46.4% compared to CNY 44,557,390.76 in Q1 2021[25] - Operating profit reached CNY 68,097,123.53, up from CNY 49,984,815.92, reflecting a growth of 36.2% year-over-year[25] - The total comprehensive income for the period was CNY 65,599,228.78, compared to CNY 56,191,602.15 in the previous year, reflecting a growth of 16.8%[25] Operating Costs and Expenses - Operating costs for Q1 2022 were ¥262,993,668.78, a 53.74% increase from ¥171,062,033.15 in the same period last year[6] - Management expenses increased by 32.80% to ¥46,423,072.18 from ¥34,956,637.22 year-on-year[6] - The total operating costs for Q1 2022 were CNY 556,118,354.19, up 28.0% from CNY 434,342,438.87 in the same period last year[24] - Research and development expenses for Q1 2022 were CNY 50,663,652.81, an increase from CNY 41,477,372.32 in Q1 2021, reflecting a growth of 22.5%[24] Cash Flow - Cash flow from operating activities showed a net outflow of ¥31,250,520.73, worsening by 17.83% compared to a net outflow of ¥26,521,957.92 in the previous year[2] - Cash flow from operating activities showed a net outflow of CNY 31,250,520.73, worsening from a net outflow of CNY 26,521,957.92 in the same period last year[27] - Investment activities resulted in a net cash outflow of CNY 42,335,286.66, compared to a significantly higher outflow of CNY 344,734,803.84 in Q1 2021[27] - Financing activities generated a net cash outflow of CNY 110,291,884.66, contrasting with a net inflow of CNY 153,925,341.73 in the previous year[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,114,260,871.65, a decrease of 0.95% from ¥4,153,513,571.28 at the end of the previous year[2] - The total assets of the company decreased slightly to CNY 4,114,260,871.65 from CNY 4,153,513,571.28, a decline of 0.9%[23] - The total liabilities decreased to CNY 1,302,692,016.01 from CNY 1,361,130,757.49, a reduction of 4.3%[22] - The company's accounts receivable rose to CNY 236,433,316.85 from CNY 209,664,837.62, indicating an increase of 12.8% year-over-year[21] - Inventory levels increased to CNY 365,478,035.13, up from CNY 330,796,256.02, representing a growth of 10.5%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,812[9] - The largest shareholder, Li Shaobo, holds 25.26% of shares, totaling 142,685,648 shares[9] - The company repurchased 6,301,087 shares, accounting for 1.12% of the total share capital, with a total transaction amount of ¥158.51 million[10] - The company plans to repurchase shares with a total fund not exceeding RMB 200 million and not less than RMB 120 million, with a maximum repurchase price of RMB 35.00 per share[13] Investment Activities - The company reported a significant increase in investment income, reaching ¥1,503,248.28, compared to a loss of ¥14,290,775.19 in the same period last year, marking a 110.52% improvement[6] - The company has established a joint venture with EOFLOW, investing RMB 54 million for a 60% stake, with a total investment of RMB 90 million[16] - The joint venture, Changsha Funuo Medical Technology Co., Ltd., completed its business registration in January 2022[18] - The company issued 5 million convertible bonds with a total amount of RMB 50 million, which began trading on January 12, 2021, with a maturity of six years[15] - As of March 31, 2022, 306 convertible bonds have been converted into 859 shares of the company, leaving 4,999,694 convertible bonds outstanding[15] Governance and Management - The company revised its articles of association and various internal regulations to enhance management and governance structures[19] Cash and Cash Equivalents - The company's cash and cash equivalents at the end of the reporting period amounted to RMB 787,831,742.36, down from RMB 902,351,183.44 at the beginning of the year[20] - Cash and cash equivalents at the end of the period stood at CNY 405,422,683.95, down from CNY 663,363,588.54 at the end of Q1 2021[27]